Sanofi Genzyme, which specializes in rare diseases, said it will let go of 130 workers at its Allston Landing biomanufacturing facility in Boston.
News of the layoffs comes on the heels of Sanofi reporting strong fourth-quarter global growth of 16.8% for the unit “due to contributions from the new immunology franchise,” the company reported Wednesday. For the full year, Genzyme’s global sales were up 15.2% at $6.97 billion.
Overall, however, Sanofi reported a 29.5% fourth-quarter decline ($897 million) and 22.8% ($3.84 billion) slide for the year that some analysts partly attribute to a hit to sales of its diabetes drugs Lantus and Toujeo on CVS Health and UnitedHealthcare formulary exclusions.
Sanofi bought Genzyme in 2011 for more than $20 billion. Sanofi has about 5,000 employees in Massachusetts located at six sites in the state.
“We are currently implementing a change at our Allston Landing plant that will result in a reduction in headcount,” Sanofi spokeswoman Ashleigh Koss told Fierce in an e-mail. “This change is associated with the outsourcing of certain aspects of the production process and various improvements to technology and operations that have been implemented. As a result, we are reducing staffing levels to more closely align with the current level of activity at the site.”
Like others in the industry, Sanofi has adapted to tougher payer tactics by reshaping itself partly through M&A and layoffs. As part of those efforts, the company noted Wednesday of the possible sale of its European generics business. That sale could happen in the second half of 2018. Reports have pegged the unit value at around $2.4 billion with two drugmakers and several private equity companies the likely bidders.
By Joseph Keenan
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
